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PMH3
A COST-EFFECTIVENESS COMPARISON OF
OLANZAPINE AND RISPERIDONE IN THE
TREATMENT OF SCHIZOPHRENIA IN ITALY
Beard S1, Lothgren M2, Giudi L3, Ramacciotti F4, Nardini M5,
Berardi D6
1RTI Health Solutions, Manchester, United Kingdom; 2Eli Lilly &
Company Ltd, Windlesham, United Kingdom; 3Eli Lilly Italia
S.P.A, Florence, Italy; 4Centro di Igene Mentale di Palazzo
Boldu,Venezia, Italy; 5Policlinico di Bari, Bari, Italy; 6Instituto di
Psichiatrica, Bologna, Italy
OBJECTIVES: To assess the relative cost-effectiveness of
olanzapine compared to risperidone in the treatment of
acute episodes and long-term maintenance of schizo-
phrenia in Italy. METHODS: A decision analysis ap-
proach (based on semi-markov modelling techniques) was
used to consider the costs and health outcomes of initi-
ating treatment on patients with an acute episode of schiz-
ophrenia and a history of relapsing with no prior atypical
antipsychotic treatment. The model allowed two alterna-
tive atypical antipsychotics to be used before considering
patients as being treatment resistant. Clinical response
rates were based on changes in BPRS/PANSS scores
(40% improvement) taken from randomised clinical
trials. Relapse rates for the ﬁrst year of treatment were
based on literature estimates. Resource use data covering
periods in acute episode, stable maintenance and acute
relapse health states were based on a combination of pub-
lished data and clinical opinion. The model was used to
compare the costs and health outcomes of olanzapine
versus risperidone as 1st line treatment choices over a 3-
year period. RESULTS: The base case analysis showed
that 1st line use of olanzapine resulted in a reduction of
relapses over the 3-year period (37 versus 38 per 100
patients treated). The olanzapine 1st line strategy was
associated with an overall cost saving over risperidone of
around €50,822 per 100 patients treated (approximately
a 2% cost reduction) despite the increased drug costs
(€6.64 versus €4.19 per day). CONCLUSIONS: With 
the context of the Italian health care services the use of
olanzapine as a 1st line atypical antipsychotic appears to
provide cost-effective health outcomes advantages over
risperidone.
PMH4
ESTIMATING MEDICAL COST REDUCTION IN
TREATING SCHIZOPHRENIA WITH CLOZAPINE
Sendersky V
Duke University/Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA
OBJECTIVES: Clozapine is a drug of choice for treating
neuroleptic resistant schizophrenia, but it has serious side
effects. Risperidone has shown efﬁcacy in managing 
neuroleptic-resistant schizophrenia, without agranulocy-
tosis. To our knowledge, economic evaluations of both
drugs in this patient population have not been performed.
The objective of this study was to estimate a difference in
hospitalization costs for schizophrenic patients on cloza-
pine vs. risperidone over one-year period. METHODS:
Estimates of length of stay (LOS) reduction in patients
receiving the clozapine or risperidone were obtained from
the medical literature by searching MEDLINE and
HEALTHSTAR. Two articles examining LOS reduction
for patients receiving risperidone and clozapine were
identiﬁed, and yearly reduction in LOS was examined. To
estimate a reduction in hospitalization costs, average
daily hospitalization charges from the Healthcare Cost
and Utilization Project database were obtained for 
the diagnosis of schizophrenia (deﬁned as ICD9-
codes 295.40–295.45, 295.80–295.82, 295.85, 295.90–
295.92, and 295.95). Hospital charges were converted to
costs by using a cost-to-charge ratio. All costs were
expressed in 2000 US dollars. RESULTS: After starting
risperidone, 35 patients had a decrease in LOS by 51 days
per year. After starting clozapine, 172 patients had a 132-
day decrease in LOS per year, with a difference of 81 
hospitalization days, favoring clozapine. The resulting
difference in hospitalization costs between patients on
clozapine and risperidone patients was estimated as
$1,052 per inpatient day. Estimated beneﬁts of reducing
hospitalization costs for clozapine patients as compared
to risperidone were $85,212 per patient per year. CON-
CLUSIONS: Clozapine seems to result in reduction in
LOS, potentially leading to lower costs of treating schiz-
ophrenic patients, as compared to risperidone. More
studies are necessary to quantify economic impact of
clozapine in this patient population.
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A DISCRETE EVENTS MODEL OF LONG-TERM
OUTCOMES AND COST OF TREATMENT WITH
LONG ACTING RISPERIDONE IN
SCHIZOPHRENIA
Heeg BM1, van Aalst G2, van den Arend IJ3, Mehnert A4,
van Hout B1
1PharMerit BV, Capelle a/d IJssel, Netherlands; 2Mentrum
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OBJECTIVE: To estimate the costs and effects of 
long-acting risperidone (the ﬁrst long-acting injectable
atypical) as ﬁrst-line treatment for non-compliant schizo-
phrenic patients, versus a conventional depot and con-
tinuing short-acting oral atypical formulations over a ﬁve
year period in the Netherlands. METHODS: A discrete
event model was developed comparing three scenarios. In
scenario 1, patients start with haloperidol depot, after
which they may be treated with olanzapine and clozap-
ine. Scenario 2 is similar to 1 except that patients start
with long-acting risperidone. In scenario 3, patients start
(or continue) with olanzapine, after which they may sub-
sequently be treated with risperidone (oral) and clozap-
ine. The model takes account of patient characteristics
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and time dependent variables. Patient characteristics are
age, gender, severity, being prone to side effects and the
potential to be dangerous. Variables changing in time are
outpatient visits, being in a psychotic episode, symptom
score, treatment, compliance, having side effects and
treatment location. Dependencies are taken into account.
Costs are calculated guided by visits, medication and
location. Outcomes are expressed in terms of the number
and duration of psychotic episodes and the cumulative
PANSS-score. Information on treatment alternatives,
transition probabilities, model structure and health care
utilisation was derived from literature and an expert
panel. RESULTS: It is estimated that ﬁrst-line treatment
with long-acting risperidone is economically dominant
over the alternatives. Per 1000 patients, it is estimated to
prevent approximately 200 and 410 relapses in ﬁve years
compared to scenario 1 and 3. Correspondingly, it is 
estimated to save €15,115 and €6,972 per patient. 
Sensitivity analyses show that the conclusion of economic
dominance is very robust. CONCLUSION: Long-acting
risperidone combines additional effectiveness with cost
savings in patients with a high probability of being 
non-compliant, and should be preferred ﬁrst-line treat-
ment over oral atypicals and conventional depots.
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DIRECT MEDICAL COSTS FOR TREATMENT OF
PATIENTS EXPERIENCING BIPOLAR DISORDER
EPISODES IN THE UK
Finnern HW1, Lothgren M1, Gandhi G2
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OBJECTIVE: To estimate resource use and direct medical
costs associated with treatment of Bipolar I Disorder
(BPDI) and Bipolar II Disorder (BPDII) episodes in the
UK. METHODS: A retrospective chart review was con-
ducted covering 19 months of observations on a sample
of 134 UK patients aged 18 years or over (average age
48.4 years) diagnosed with Bipolar Disorder. RESULTS:
Patients with BPDI experienced an average of 1.11
episodes per year whilst BPDII patients experienced 1.21
episodes per year. The yearly average direct cost for
patients who experienced at least one episode during the
study period was £7,714 for BPDI patients (n = 68) and
£2,980 for BPDII patients (n = 25). There were 103 
hospitalisations during the study period and these 
hospitalisations formed the major component of the total
treatment costs with a yearly average hospitalisation cost
of £6,280 for BPDI patients and £1,636 for BPDII
patients. The average yearly drug cost for BPDI patients
was found to be £383 (5% of total cost) and £194 (6.5%
of total cost) for BPDII patients. Manic Episodes required
twice as many hospitalisations per episode and were 
associated with a longer length of stay in hospital com-
pared with Depressive Episodes. The average length of
stay in hospital was 65 days for Manic, 46 days for
Mixed and 36 days for Depressive Episodes. The average
hospital cost was found to be £7,015 for a Manic
Episode, £4,574 for a Mixed Episode and £3,787 for a
Depressive Episode. CONCLUSIONS: The average treat-
ment cost of a BPDI patient was found to be more than
twice the cost of a BPDII patient. The cost difference is
driven by the ﬁnding that Manic Episodes required more
hospitalisations and were associated with a longer length
of hospital stay compared with Mixed or Depressive
Episodes.
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BOTTOM-UP OR TOP-DOWN? IMPACT OF
PATIENT SELECTION ON COST-OF-ILLNESS
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OBJECTIVES: Currently in the Netherlands a ran-
domised clinical trial is executed to compare two 
outpatient psychotherapies for patients with Borderline
Personality Disorder (BPD). The goal of the present study
was to calculate the cost-of-illness (COI) of BPD for
Dutch Society. METHODS: We used a prevalence-based
approach, which takes into account total yearly costs of
all patients who are diagnosed with BPD at a certain point
in time. COI was calculated both top-down and bottom-
up. For top-down calculation, prevalence ﬁgures from
existing registrations and costs of the Dutch health care
system from government publications were used. Baseline
cost interviews of 88 BPD-patients in the trial were used
to estimate bottom-up COI. BPD was deﬁned according
to ICD-9 and ICD-10 (top-down) and DSM-IV (bottom-
up) classiﬁcations. RESULTS: Based on literature, 
prevalence of BPD in the Dutch general population was
estimated at 1.1%. For all cost items, large differences
arise between the bottom-up and the top-down approach.
Total yearly societal are €200,184,828 top-down, and 16
times as high €3,258,240,100 for bottom-up. Healthcare
costs represent 0.03% and 1.03% of total Dutch health
care expenditure, respectively. CONCLUSION: Our
results show large differences between the two methods.
The top-down ﬁgure probably is an underestimation of
true costs due to incomplete registrations. On the other
hand, the bottom-up patient group may not be represen-
tative of the Dutch BPD population because of the in-en
exclusion criteria used in the trial, which exclude the very
mild and the very severe cases. In conclusion, we recom-
mend to assess COI and prevalence in a combined design.
First, prevalence in the general population is assessed.
Subsequently, those subjects diagnosed with the disease
under study should be followed, receiving care as usual,
in order to determine COI. This is the only way to match
bottom-up patient group and total population.
